Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
92 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Actinic (Solar) Keratosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H2 2014', provides an overview of the Actinic (Solar) Keratosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Actinic (Solar) Keratosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Actinic (Solar) Keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Actinic (Solar) Keratosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Actinic (Solar) Keratosis Overview 9 Therapeutics Development 10 Pipeline Products for Actinic (Solar) Keratosis - Overview 10 Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis 11 Actinic (Solar) Keratosis - Therapeutics under Development by Companies 12 Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes 14 Actinic (Solar) Keratosis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Actinic (Solar) Keratosis - Products under Development by Companies 19 Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes 20 Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development 21 Biofrontera AG 21 Galderma S.A. 22 LEO Pharma A/S 23 Clinuvel Pharmaceuticals Limited 24 3M Drug Delivery Systems 25 G&E Herbal Biotechnology Co., Ltd. 26 Paloma Pharmaceuticals, Inc. 27 Digna Biotech, S.L. 28 Foamix Ltd. 29 Kinex Pharmaceuticals, LLC 30 Promius Pharma, LLC 31 Genextra S.p.a. 32 Novelix Pharmaceuticals, Inc. 33 Advancell 34 Dolorgiet Gmbh & Co. Kg 35 Spherium biomed S.L. 36 Actinic (Solar) Keratosis - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Target 38 Assessment by Mechanism of Action 41 Assessment by Route of Administration 44 Assessment by Molecule Type 46 Drug Profiles 48 aminolevulinic acid hydrochloride - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 afamelanotide - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SRT-100 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 resiquimod - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AK-3012 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 DAC-0060 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 AD-17137 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ACT-01 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 LEO-43204 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 disitertide - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 KX-01 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 P-529 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CUV-9900 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NVX-207 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ANS-401 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 ANS-403 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 imiquimod - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 854-A - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Drug for Actinic Keratosis - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Ingenol Mebutate Analogs for Dermatology and Cancer - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 SP-12054 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Actinic (Solar) Keratosis - Recent Pipeline Updates 76 Actinic (Solar) Keratosis - Dormant Projects 82 Actinic (Solar) Keratosis - Discontinued Products 83 Actinic (Solar) Keratosis - Product Development Milestones 84 Featured News & Press Releases 84 Aug 20, 2014: Biofrontera files litigation against former supplier 84 Oct 21, 2013: Allergan launches Ameluz in Spain 84 Sep 20, 2013: Biofrontera: Actinic keratosis, most efficiently treated by Ameluz, recognized as occupational disease 85 Feb 19, 2013: Chugai Pharma Files Lawsuit On Patent Infringement Concerning Oxarol Ointment And Petition For Provisional Disposition Order 86 Jan 08, 2013: Biofrontera Receives Positive EMA Opinion On Extended Storage Conditions For Ameluz 86 Nov 05, 2012: Biofrontera Launches Ameluz In UK And Austria 87 Oct 15, 2012: Biofrontera And Bipharma Announce Launch Of Ameluz In Netherlands 88 Aug 13, 2012: Biofrontera Signs Distribution Agreement With Pelpharma For Marketing Of Ameluz In Austria 88 Jul 24, 2012: Biofrontera Signs Distribution Agreement With Spirit Healthcare For Marketing Ameluz In UK And Ireland 89 Jul 23, 2012: Biofrontera Discusses Approval Of Ameluz In US With FDA 89 Appendix 91 Methodology 91 Coverage 91 Secondary Research 91 Primary Research 91 Expert Panel Validation 91 Contact Us 92 Disclaimer 92
List of Tables Number of Products under Development for Actinic (Solar) Keratosis, H2 2014 10 Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Investigation by Universities/Institutes, H2 2014 20 Actinic (Solar) Keratosis - Pipeline by Biofrontera AG, H2 2014 21 Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2014 22 Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2014 23 Actinic (Solar) Keratosis - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2014 24 Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2014 25 Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2014 26 Actinic (Solar) Keratosis - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 27 Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2014 28 Actinic (Solar) Keratosis - Pipeline by Foamix Ltd., H2 2014 29 Actinic (Solar) Keratosis - Pipeline by Kinex Pharmaceuticals, LLC, H2 2014 30 Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2014 31 Actinic (Solar) Keratosis - Pipeline by Genextra S.p.a., H2 2014 32 Actinic (Solar) Keratosis - Pipeline by Novelix Pharmaceuticals, Inc., H2 2014 33 Actinic (Solar) Keratosis - Pipeline by Advancell, H2 2014 34 Actinic (Solar) Keratosis - Pipeline by Dolorgiet Gmbh & Co. Kg, H2 2014 35 Actinic (Solar) Keratosis - Pipeline by Spherium biomed S.L., H2 2014 36 Assessment by Monotherapy Products, H2 2014 37 Number of Products by Stage and Target, H2 2014 40 Number of Products by Stage and Mechanism of Action, H2 2014 43 Number of Products by Stage and Route of Administration, H2 2014 45 Number of Products by Stage and Molecule Type, H2 2014 47 Actinic (Solar) Keratosis Therapeutics - Recent Pipeline Updates, H2 2014 76 Actinic (Solar) Keratosis - Dormant Projects, H2 2014 82 Actinic (Solar) Keratosis - Discontinued Products, H2 2014 83
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
